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Abstract
Purpose Entecavir demonstrated superior virologic and
biochemical beneﬁts over lamivudine at 48 weeks in
nucleoside-naı ¨ve Chinese patients with chronic hepatitis
B (CHB). We evaluated the effect of continued entecavir
and lamivudine treatment in patients who continued treat-
ment in year 2 and the off-treatment durability of patients
who achieved a protocol-deﬁned consolidated response at
week 48.
Methods Chinese adults (n = 519) with CHB were ran-
domized to a minimum of 52 weeks of treatment with
entecavir 0.5 mg/day or lamivudine 100 mg/day. Patients
with a consolidated response at week 48 (HBV DNA\0.7
MEq/ml for C24 weeks, ALT \1.25 times ULN, and, if
HBeAg(?) at baseline, loss of HBeAg for at least
24 weeks) stopped treatment at week 52 and were followed
off-treatment. Patients with a partial response at week 48
(HBV DNA\0.7 MEq/ml in the absence of other criteria
for a consolidated response) could continue blinded treat-
ment for up to 96 weeks. Patients were assessed for HBV
DNA, ALT normalization, safety, and, if HBeAg(?)a t
baseline, for HBe seroconversion. Cumulative proportions
of all treated patients who ever achieved these responses
were also analyzed.
Results Among patients treated during year 2 (entecavir:
n = 193; lamivudine: n = 145), 74% of entecavir-treated
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DOI 10.1007/s12072-008-9088-8and 41% of lamivudine-treated patients had HBV DNA
\300 copies/ml by PCR at end of dosing and 96% of
entecavir-treated and 82% of lamivudine-treated patients
normalized ALT. Eleven percent of entecavir-treated ver-
sus 19% of lamivudine-treated patients underwent HBe
seroconversion during year 2. Cumulative conﬁrmed
analysis for all treated patients through 96 weeks showed
that 79% of entecavir-treated versus 46% of lamivudine-
treated patients (p\0.0001) achieved HBV DNA
\300 copies/ml by PCR. Similar proportions of entecavir-
and lamivudine-treated patients achieved conﬁrmed ALT
normalization and HBe seroconversion. Safety proﬁle was
comparable for both treatment groups.
Conclusions Through 96 weeks of treatment, entecavir
resulted in continued clinical beneﬁt in nucleoside-naı ¨ve
Chinese patients with CHB, with a safety proﬁle compa-
rable with lamivudine.
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Abbreviations
ALT Alanine aminotransferase
HBV Hepatitis B virus
HBeAg Hepatitis B e antigen
HCC Hepatocellular carcinoma
ULN Upper limit of normal
Introduction
Approximately 400 million people are chronically infected
withHBV,andtheworldwideburdenofhepatitisBisgreatest
in China, where vertical transmission of HBV predominates
[1]. HBV contributes directly to the increased risk of liver
disease in patients with chronic hepatitis B (CHB) [2–4]. A
linear dose–response relationship exists between the con-
centration of HBV DNA in serum and the risk of developing
cirrhosis and HCC in this population [2, 3]. Suppressing
replication of HBV with nucleoside analogues reduces mor-
bidity and mortality in patients with CHB and advanced
hepaticﬁbrosis[5].Thegoaloftherapy for CHB, therefore,is
arapidandsustainedreductionoftheserumHBVDNAtothe
lowest possible level [6]. Durable suppression of HBV DNA
replication, in turn, results in histologic improvement, nor-
malization of ALT, and in some patients with HBeAg(?)
infection, seroconversion to an anti-HBe state.
The emergence of resistant viral strains is an important
consideration when selecting a nucleoside analogue. The
very large pool of HBV in circulation, the rapid turnover
rate, and the high error rate in HBV replication mean that
any potential mutant, including those that give rise to drug
resistance, may be present in a patient before he or she
starts therapy [7]. The emergence of lamivudine resistance
before and during therapy limits the usefulness of this drug.
The prevalence of lamivudine genotypic resistance is
reported to be 24, 42, and 70% after 1, 2, and 4 years of
continuous treatment, respectively [8]. An adefovir phase
III trial in HBeAg(-) patients reports cumulative proba-
bilities of genotypic resistance to adefovir at 1, 2, 3, 4, and
5 years of 0, 3, 11, 19, and 30%, respectively [9]. Tel-
bivudine selects for mutations in the YMDD motif and,
although it is associated with lower resistance than lami-
vudine, recently reported virologic breakthrough due to
resistance substitutions was 21.6% and 8.6% in HBeAg(?)
and HBeAg(-) patients after 2 years of treatment [10]. The
lowest reported rates of resistance after 5 years of treat-
ment have been obtained with entecavir (\1%) [7, 11, 12].
Entecavir, a potent guanosine analogue, signiﬁcantly
increased survival in an animal model of chronic HBV
infection [13]. Entecavir (0.5 mg/day for nucleoside-naı ¨ve
patients or 1 mg/day for lamivudine-refractory patients)
produced signiﬁcant virologic, histologic, and biochemical
improvement in a series of large randomized multicenter
phase III trials that encompassed a broad spectrum of
clinical situations, including nucleoside-naı ¨ve patients with
HBeAg(?)[ 14] and HBeAg(-) infection [15], and treat-
ment-experienced patients with lamivudine-refractory
HBV [16]. In nucleoside-naive patients, entecavir was
superior to lamivudine (100 mg/day) for histologic, viro-
logic, and biochemical outcomes, and entecavir resistance
after 1 year of treatment was rare (\1%) [11, 14]. Long-
term follow-up demonstrates that suppression of HBV
DNA replication is maintained throughout 2 and even
3–4 years of treatment with entecavir and that the rate of
resistance is less than 1% after 4 years [12, 17, 18].
The efﬁcacy and safety of entecavir have also been
studied in nucleoside-naı ¨ve Chinese patients with CHB,
76% of whom had HBV DNA\300 copies/ml by PCR
assay after 48 weeks of treatment (vs. 43% with lamivu-
dine, p\0.0001) [19]. The present analysis evaluates the
efﬁcacy and safety of entecavir and lamivudine in patients
who failed to achieve a protocol-deﬁned consolidated
response at week 48 and continued treatment in year 2, as
well as the off-treatment durability of patients who achieved
a protocol-deﬁned consolidated response at week 48.
Methods
The complete study design and patient selection criteria for
the trial have been published elsewhere [19].
Patients
Chinese patients eligible for the trial had CHB, were aged
16 years or older, and had a serum HBV DNA level
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TM branched-chain DNA assay
and an ALT level between 1.3 and 10 times the ULN. Both
HBeAg(?) and HBeAg(-) patients could be enrolled.
Participants were required to have compensated liver dis-
ease deﬁned as a total serum bilirubin level B2.5 mg/dl,
prothrombin time B3 s longer than the normal control
value (or an international normalized ratio B1.5), serum
albumin C3.0 g/dl, and no current evidence or history of
variceal bleeding or hepatic encephalopathy (i.e., Child-
Pugh class A).
Patients were excluded if they had received previous
treatment with a nucleoside or nucleotide analogue with
anti-HBV activity for 12 weeks or more at any time or had
received any anti-HBV therapy, including interferon or
thymosin alpha-1, within 24 weeks before randomization.
Patients with evidence of infection by hepatitis C or D
viruses or human immunodeﬁciency virus were excluded.
Individuals with current evidence or a history of liver or
pancreatic tumors were excluded; ultrasound was done
before randomization to conﬁrm the absence of focal
lesions suggestive of cancer.
Study design
Patients eligible for this multicenter study were random-
ized to at least 52 weeks of double-blind, double-dummy
treatment with either entecavir (Baraclude
, Bristol-Myers
Squibb) 0.5 mg once daily or lamivudine (Epivir-HBV,
GlaxoSmithKline) 100 mg once daily. The protocol-
deﬁned management of patients after week 52 was based
on the HBV DNA level as determined by Quantiplex
TM
bDNA assay (approved assay at the time of protocol
development), HBeAg status, and serum ALT level at
week 48. This design evaluated whether therapy could be
discontinued once certain treatment end points were
achieved.
Patients with a consolidated response at week 48 had
HBV DNA \0.7 MEq/ml by Quantiplex
TM bDNA assay
for at least 24 weeks, a serum ALT level\1.25 times ULN,
and, if they were HBeAg(?) at baseline, were HBeAg(-)
for at least 24 weeks (i.e., at weeks 24, 36, and 48). Indi-
viduals with a consolidated response stopped study drug
treatment at week 52 and were monitored for a further
24 weeks to determine whether they had a sustained
response.
Patients with a partial response had HBV DNA
\0.7 MEq/ml at week 48, but did not meet all of the cri-
teria for a consolidated response. Individuals with a partial
response could continue double-blind treatment until they
achieved a consolidated response or until they had com-
pleted 96 weeks of treatment, whichever came ﬁrst.
Patients with a partial response at week 48 who achieved a
consolidated response during weeks 52–96 of treatment
discontinued study drug treatment for up to 24 weeks
follow-up. Patients who experienced a virologic break-
through, deﬁned as two consecutive HBV DNA
measurements C1 log10 above nadir during weeks 52–96 of
treatment and up to 24 weeks off-treatment follow-up,
could elect to enroll in a separate entecavir protocol.
Patients with a nonresponse had HBV DNA C0.7 MEq/
ml at week 48. These individuals discontinued study drug
treatment at week 52 and were offered enrollment in an
entecavir rollover protocol or off-study alternative anti-
HBV therapy as recommended by the investigator. Patients
discontinuing entecavir were monitored for a further
24 weeks for safety.
Efﬁcacy assessment
For virologic responders who continued treatment beyond
week 48, efﬁcacy end points through 96 weeks of treat-
ment included the proportion of patients with HBV DNA
\300 copies/ml as measured by a sensitive PCR assay
(Roche COBAS Amplicor assay, limit of detection 300
copies/ml [57 IU/ml]). Other efﬁcacy end points were the
proportion of patients with normalization of serum ALT
(i.e., B1.0 times ULN) and HBeAg loss and HBe sero-
conversion (in patients who were HBeAg(?) at baseline) at
EOD (i.e., at the last on-treatment observation).
A cumulative efﬁcacy analysis using data for all treated
patients (entecavir: n = 258; lamivudine: n = 261) was
also conducted to evaluate the cumulative probability of
ever achieving a conﬁrmed end point for up to 2 years of
treatment. The cumulative conﬁrmed response is deﬁned as
the cumulative proportion of treated patients who achieved
a given endpoint (HBV DNA\300 copies/ml, ALT B1.0
times ULN, HBeAg loss or HBe seroconversion) at some
point up to and including week 96. A conﬁrmed end point
was one that was documented on two sequential mea-
surements or at the last on-treatment measurement.
Patients with a consolidated response during year 1 or 2
of treatment were evaluated for HBV DNA, ALT nor-
malization, and HBe seroconversion and monitored for
24 weeks off-treatment to determine whether they sus-
tained these responses.
Safety assessment
Safety was assessed by laboratory testing and evaluation of
adverse events during treatment and follow-up. Important
safety end points included the proportion of patients dis-
continuing treatment because of adverse events, the
proportions of patients with adverse events, serious adverse
events, laboratory abnormalities (i.e., ALT ﬂares deﬁned as
[2 times the baseline value and C10 times ULN), and
deaths.
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The details of the sample size calculation have been
described elsewhere [19]. Conﬁdence intervals and p val-
ues for differences in proportions are based on the normal
approximation to the binomial distribution, with unpooled
proportions used in the computation of the standard error of
the difference. The p values are based on 2-sided tests. For
the analysis of efﬁcacy end points for the year 2 treatment
cohort, the proportion of subjects who achieved an end
point at EOD is presented for each treatment group. No
statistical comparisons can be made of such treatment
groups. For consolidated responders at week 48 or EOD,
sustained response during the 24-week off-treatment fol-
low-up phase is also described. Safety analyses tabulate the
proportion of subjects with events on-treatment and during
off-treatment follow-up.
Results
Of 519 patients randomized and treated in year 1 (enteca-
vir: n = 258; lamivudine: n = 261), 50 (19.4%) entecavir
recipients and 40 (15.3%) lamivudine recipients achieved a
consolidated response at week 48, discontinued treatment
at week 52, and were further followed off-treatment for up
to 24 weeks. Eight (3.1%) entecavir recipients and 62
(23.8%) lamivudine-treated patients were nonresponders at
week 48 and discontinued therapy at week 52. A total of
193 (74.8%) entecavir recipients and 146 (55.9%) lami-
vudine recipients achieved a virologic response at week 48
and all but one lamivudine-treated patient continued ther-
apy in year 2 of the trial. The ﬂow of patients through the
trial is depicted in Fig. 1. Baseline characteristics of
patients have been presented elsewhere [19].
During year 2 of the study, fewer entecavir-treated than
lamivudine-treated patients discontinued treatment (16 vs.
50). Reasons for discontinuing treatment included virologic
breakthrough (entecavir: n = 6; lamivudine: n = 46), lost
to follow-up (entecavir: n = 4; lamivudine: n = 1), with-
drawal of consent (entecavir: n = 2; lamivudine: n = 2),
pregnancy (entecavir: n = 1; lamivudine: n = 1), noncom-
pliance (entecavir: n = 1), and other reasons (entecavir:
n = 2).Themediantimeontherapyforpatientstreatedwith
entecavirwas95.7 weeks,with177patientscompletingyear
2. The median time on therapy for patients treated with
lamivudine was 66.7 weeks, with 95 patients completing
year 2.
Virologic, biochemical, and serologic responses
Virologic response
Among subjects treated in year 2 (entecavir: n = 193;
lamivudine: n = 145), the mean change from baseline in
HBV DNA by PCR assay (log10 copies/ml) remained sta-
ble between week 48 and EOD in the entecavir group
(-6.09 and -6.04, respectively) and decreased in the
lamivudine group (-5.16 at week 48, -3.92 at EOD). The
proportion of patients with HBV DNA\300 copies/ml by
PCR was maintained throughout year 2 of treatment with
entecavir. A total of 76% and 74% of entecavir-treated
patients had HBV DNA\300 copies/ml at week 48 and at
EOD, respectively (Table 1). In comparison, fewer lami-
vudine-treated patients had HBV DNA \300 copies/ml
after 1 year of treatment (52%) and the proportion declined
to 41% at EOD (Table 1).
Among all treated patients, the cumulative proportion of
patients with HBV DNA\300 copies/ml was signiﬁcantly
Fig. 1 Study design through 96 weeks
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123greater (p\0.0001) among patients treated with entecavir
(204/258; 79%) than among those treated with lamivudine
(121/261, 46%) (Table 2).
Biochemical response
Most patients in the year 2 cohort had ALT B 1.0 times
ULN at week 48. While proportions of patients with nor-
malized ALT increased at EOD among entecavir-treated
patients (91% at week 48, 96% at EOD), they declined
among patients treated with lamivudine (88% at week 48
and 82% at EOD) (Table 1).
Among all treated patients, the cumulative proportion
with conﬁrmed ALT normalization (B1.0 times ULN)
through 96 weeks was greater among patients treated with
entecavir (248/258; 96%) than lamivudine (241/261, 92%)
(p = 0.06) (Table 2).
Serologic response
Among HBeAg(?) patients included in the year 2 cohort,
8% of entecavir recipients (15/186) and 17% of lamivu-
dine-treated patients (23/135) had lost HBeAg after 1 year
of dosing. At EOD in these individuals, 18% of entecavir
recipients (34/186) and 25% of lamivudine-treated patients
(34/135) had lost HBeAg, and 11% of entecavir recipients
(20/186) and 19% of lamivudine-treated patients (25/135)
had undergone HBe seroconversion (Table 1).
Among patients who were HBeAg(?) at baseline, the
cumulative proportion with conﬁrmed loss of HBeAg
through 96 weeks was 27% for both treatment groups (ent-
ecavir: n = 61/225; lamivudine: n = 59/221) (Table 2).
The cumulative proportion with conﬁrmed HBe serocon-
versionwas21%inthosetreatedwithentecavir(48/225)and
23%inthosetreatedwithlamivudine(51/221)(Table 2).No
patients lost HBsAg during the trial.
Protocol-deﬁned outcomes through year 2
During year 2 of therapy, an additional 27 of 193 (14%)
entecavir-treated and 23 of 145 (16%) lamivudine-treated
patients achieved the protocol-deﬁned response of HBV
DNA level\0.7 mEq/ml, ALT\1.25 times ULN, and loss
of HBeAg (if HBeAg[?]).
Over the full 96-week duration of the study, 77 of 258
(29.8%) patients on entecavir (50 at week 48, plus 27
during year 2) had a consolidated response, as compared
with 63 of 261 (24.1%) patients on lamivudine (40 at week
48, plus 23 during year 2). Fewer entecavir-treated (11,
4%) than lamivudine-treated patients (108, 41%) were
deemed to be nonresponders throughout the 96 weeks of
treatment.
Patients with sustained response
At week 48 or EOD, 76 (99%) entecavir-treated patients
with a consolidated response had HBV DNA\300 copies/
ml, 73 (95%) had ALT normalization, and 36 of 45 (80%)
HBeAg(?) patients had achieved HBe seroconversion.
These results were sustained in 24, 85, and 78% of patients,
respectively, at the end of follow-up.
At week 48 or EOD, 54 (86%) lamivudine-treated
patients with a consolidated response had HBV DNA
\300 copies/ml, 62 (98%) had ALT normalization, and 27
of 30 (90%) HBeAg(?) patients had achieved HBe sero-
conversion. These results were sustained in 17, 63, and
78% of patients, respectively, at the end of follow-up.
Table 1 Proportions achieving virologic, biochemical, and serologic
end points in the second year treatment cohort
a
Entecavir (N = 193) Lamivudine (N = 145)
Virologic end point
HBV DNA\300 copies/ml by PCR assay, n (%)
Week 48 147 (76) 76 (52)
End of dosing 142 (74) 60 (41)
Biochemical end point
ALT normalization (B1 times ULN), n (%)
Week 48 175 (91) 128 (88)
End of dosing 185 (96) 119 (82)
Serologic end point
HBeAg seroconversion, n (%)
Week 48 14/186 (8) 21/135 (16)
End of dosing 20/186 (11) 25/135 (19)
a All patients in the year 2 treatment cohort had HBV DNA
\0.7 MEq/ml by the end of year 1
Table 2 Cumulative conﬁrmed proportions achieving virologic,
biochemical, and serologic end points through week 96 in all the
treated cohorts
Entecavir
(N = 258)
Lamivudine
(N = 261)
Virologic end point
HBV DNA\300 copies/ml by
PCR assay, n (%)
204 (79) 121 (46)
p \0.0001
Biochemical end point
ALT normalization (B1 times
ULN), n (%)
248 (96) 241 (92)
p 0.06
Serologic end points
HBeAg loss, n (%) 61/225 (27) 59/221 (27)
p NS
HBeAg seroconversion, n (%) 48/225 (21) 51/221 (23)
p NS
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During year 2 of the study, the proportion of entecavir- and
lamivudine-treated patients with adverse events was 29%
and 23%, respectively. Most of these events were graded as
mild and considered to be unrelated to study drug. No
entecavir-treated patients had serious adverse events or on-
treatment ALT ﬂares during the second year of treatment.
In contrast, 5 (3%) lamivudine-treated patients had serious
adverse events and 4 (3%) had on-treatment ALT ﬂares.
Among all treated patients through 96 weeks, study
treatments were generally well tolerated and the adverse
event proﬁles were generally comparable for entecavir and
lamivudine (Table 3). The most common adverse events
considered by investigators to be related to treatment with
entecavir or lamivudine were fatigue (2% vs. 6%, respec-
tively) and increased serum ALT level (3% vs. 6%,
respectively). A total of 11 (4%) entecavir recipients had
ALT ﬂares during treatment, and all of these ﬂares were
associated with a C2 log10 reduction in HBV DNA level. A
total of 18 (7%) lamivudine recipients had ALT ﬂares
during treatment. Nine of these ﬂares were associated
with a C2 log10 reduction in HBV DNA level, and 8 were
associated with increased HBV DNA. Furthermore, 1
lamivudine recipient had an ALT increase and discontin-
ued therapy at week 3, with no recorded on-treatment HBV
DNA.
The proportion of patients who experienced serious
adverse events during treatment was low and comparable
for the two treatment groups (3% and 6% of patients
treated with entecavir and lamivudine, respectively).
Increased serum ALT level was the most common on-
treatment serious adverse event reported in 5 (2%) ente-
cavir recipients and 12 (5%) lamivudine recipients.
During untreated follow-up, the overall frequency of
adverse events was 24% among entecavir recipients and
28% among lamivudine recipients. The most common
adverse event in this setting was increased serum ALT
level occurring in 8% of entecavir-treated and 18% of
lamivudine-treated patients. Off-treatment ALT ﬂares were
reported in 4 (5%) entecavir recipients and 8 (10%) lami-
vudine recipients; all but one of these ALT ﬂares occurred
in the setting of increased HBV DNA. All ALT ﬂares
resolved after restarting alternative HBV treatment or
entecavir.
Discussion
We previously presented the results of the 48-week anal-
ysis of this study population of nucleoside-naı ¨ve Chinese
patients with CHB [19]. The results presented here conﬁrm
and extend the original 48-week ﬁndings, presenting fol-
low-up data for (1) patients who achieved a consolidated
response and discontinued therapy; (2) patients who were
partial responders and continued in year 2; and (3) an
additional analysis evaluating cumulative conﬁrmed
responses. Patients who continued or discontinued treat-
ment in year 2 were dependent on response achieved in
year 1 and had varied response for each drug. Therefore, no
statistical analysis is presented for treatment arms of either
cohorts, and results for this cohort are descriptive of what
happened to patients who continue or discontinue treatment
during the second year.
Among the year 2 cohort, suppression of HBV replica-
tion was maintained among patients treated with entecavir
but waned in those treated with lamivudine. The proportion
of patients with HBV DNA\300 copies/ml by PCR after
48 weeks and at EOD with entecavir was 76% and 74%,
respectively, but 52% and 41%, respectively, among those
treated with lamivudine.
This same pattern is apparent in the rate of ALT nor-
malization in the year 2 cohort. The proportion of
recipients with normal ALT after 48 weeks and at EOD
was 91% and 96%, respectively, for entecavir, and 88%
and 82%, respectively, for lamivudine.
Among patients initiating treatment with entecavir, 79%
had conﬁrmed suppression of HBV DNA replication below
the limit of detection (\300 copies/ml by PCR) and 96%
had conﬁrmed normalization of ALT (B1 times ULN)
during the trial. These cumulative end points were
achieved in 46% and 92% of patients who initiated treat-
ment with lamivudine.
Overall, 240 of 258 (93%) patients who initiated treat-
ment with entecavir had a consolidated or partial response
through 96 weeks of follow-up. In contrast, 139 of 261
(53%) patients who initiated treatment with lamivudine had
Table 3 Cumulative safety data through 96 weeks of treatment
On-treatment through
week 96
n (%)
Entecavir
(N = 258)
Lamivudine
(N = 261)
Any AE 166 (64) 156 (60)
Grade 3–4 AE 18 (7) 23 (9)
Serious AE 9 (3) 16 (6)
Discontinuation due to AE 1 (\1) 3 (1)
On-treatment ALT ﬂare
a 11 (4) 18 (7)
Off-treatment ALT ﬂare
b 4
c (5) 8
c (10)
a On-treatment ALT ﬂare = ALT[2 times baseline and[10 times
ULN
b Off-treatment ALT ﬂare = ALT[2 times reference and [10
times ULN (reference is minimum of baseline laboratory value and
last laboratory value at end of dosing)
c Entecavir off-treatment, n = 88; lamivudine off-treatment, n = 78
Abbreviation: AE, adverse event
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important to comment that the protocol-deﬁned manage-
ment criteria used in this study (undetectable HBV DNA
by bDNA assay and HBeAg loss [instead of seroconver-
sion]) were selected more than 5 years ago and no longer
reﬂect current practice. Therefore, it is possible that off-
treatment results may underestimate the durability of
responses that would be observed in patients who had
achieved undetectable HBV DNA by PCR and had instead
a consolidated HBe seroconversion.
Another limitation is that this population was not ana-
lyzed for the lamivudine resistance genotype, which may
explain the lamivudine results. However, nucleoside-naı ¨ve
patients have been shown to possess less resistance to
entecavir than lamivudine [20]. This may be the product of
the rapid, maintained suppression of HBV replication with
entecavir, combined with a requirement for multiple sub-
stitutions in nucleoside-naı ¨ve patients.
These data compare well with that obtained in two large
randomizedinternationalphaseIIItrialsinpatientswithCHB
[14, 15], both of which had similar inclusion and exclusion
criteriaandmanagementprotocolstothatofthepresentstudy.
Among HBeAg(?) patients, 67% of entecavir recipients and
36%oflamivudinerecipientshadHBVDNA\300 copies/ml
after 52 weeks [14]. Patients with a virologic response
(\0.7 MEq/ml), who remained HBeAg(?) after 1 year (i.e.,
partial responders), were eligible to continue therapy for a
secondyear.Through96 weeks,thecumulativeproportionof
patients with HBV DNA\300 copies/ml was 80% in those
treated with entecavir and 39% in those treated with lamivu-
dine (p\0.0001) [17]. Similarly, among HBeAg(-)
patients, 90% of entecavir recipients and 72% of lamivudine
recipientshadHBVDNA\300 copies/mlafter52 weeksina
randomized phase III study (p\0.001) [15]. Although most
entecavir- and lamivudine-treated patients discontinued
therapy after 52 weeks because of protocol design, the
cumulative proportion of patients achieving HBV DNA
\300 copies/ml through week 96 was 94% for entecavir-
treatedand77%forlamivudine-treatedpatients(p\0.0001)
[21]. Cumulative proportion of patients with ALT normali-
zationwas89%forentecavir-treatedand84%forlamivudine-
treated patients (p[0.05) [21].
Preliminary results of a small, randomized multicenter
viral kinetic study show that treatment with 0.5 mg of
entecavir was superior to 10 mg of adefovir for the primary
efﬁcacy end point of mean change from baseline in HBV
DNA at week 12 [22]. At week 48, mean HBV DNA
changes from baseline were -7.28 log10 copies/ml for
entecavir as compared with -5.08 log10 copies/ml for
adefovir (difference [95% CI]: -1.86 [-2.69, -1.03]), and
58% of entecavir-treated patients as compared with 19% of
adefovir-treated patients achieved undetectable HBV DNA
(\300 copies/ml) by PCR at week 48 [23].
The short-term differences in potency between entecavir
and adefovir would be expected to translate into long-term
differences in clinical efﬁcacy, although these two drugs
have not been directly compared in a large, long-term
study. The mean reduction in HBV DNA at EOD with
entecavir in the present study was -6.04 log10 copies/ml.
In a separate study, the corresponding decrease in HBV
DNA after 2 years of treatment with adefovir in HBeAg(-)
patients was -3.47 log10 copies/ml [24]. These data from
different studies must be interpreted with caution, but
suggest that entecavir provides more profound long-term
suppression of HBV DNA replication. If this is the case,
then entecavir may be preferred over adefovir as a ﬁrst-line
treatment option for CHB.
Treatment was well tolerated throughout 2 years of
therapy, with no substantial differences between entecavir
and lamivudine. Fewer ALT ﬂares (on- and off-treatment)
were observed with entecavir than with lamivudine. Most
ALT ﬂares during treatment with entecavir were associated
with reductions in HBV DNA. In contrast, 44% of those
that occurred with use of lamivudine were associated with
increased HBV DNA.
In conclusion, entecavir provides profound suppression
of HBV replication that is durable for a period of at least
2 years in nucleoside-naı ¨ve Chinese patients with CHB. In
contrast, the efﬁcacy of lamivudine was shown to wane
over time. Among those treated with entecavir, the pro-
portion of patients with a consolidated response actually
increased in year 2 of treatment. The results of this study
conﬁrm and extend the ﬁndings of the phase III clinical
trial program that has demonstrated superior virologic and
biochemical efﬁcacy with entecavir than with lamivudine.
Available data suggest that entecavir is a preferred ﬁrst-line
nucleoside analogue for CHB.
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